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We recently described the novel anti-persister compound 1-[(2,4-
dichlorophenethyl)amino]-3-phenoxypropan-2-ol (SPI009), capable of directly killing
persister cells of the Gram-negative pathogen Pseudomonas aeruginosa. This
compound also shows antibacterial effects against non-persister cells, suggesting
that SPI009 could be used as an adjuvant for antibacterial combination therapy.
Here, we demonstrate the broad-spectrum activity of SPI009, combined with
different classes of antibiotics, against the clinically relevant ESKAPE pathogens
Enterobacter aerogenes, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, P. aeruginosa, Enterococcus faecium and Burkholderia cenocepacia and
Escherichia coli. Importantly, SPI009 re-enabled killing of antibiotic-resistant strains
and effectively lowered the required antibiotic concentrations. The clinical potential
was further confirmed in biofilm models of P. aeruginosa and S. aureus where SPI009
exhibited effective biofilm inhibition and eradication. Caenorhabditis elegans infected
with P. aeruginosa also showed a significant improvement in survival when SPI009 was
added to conventional antibiotic treatment. Overall, we demonstrate that SPI009, initially
discovered as an anti-persister molecule in P. aeruginosa, possesses broad-spectrum
activity and is highly suitable for the development of antibacterial combination therapies
in the fight against chronic infections.
Keywords: antibacterials, P. aeruginosa, ESKAPE pathogens, anti-persister therapies, antibiotic resistance
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INTRODUCTION
Antibiotic resistance is rapidly increasing in the majority of
nosocomial pathogens, complicating the effective treatment
of bacterial infections and transforming once easily cured
diseases into serious human health threats (European Centre for
Disease Prevention and Control, 2013; O’Neill, 2016). Although
selection for resistance in microorganisms is inevitable, the
widespread and excessive use of antibiotics allowed pathogens
to efficiently adapt to these stressful conditions, resulting in
the occurrence of extensively drug-resistant and pan-drug
resistant strains (Livermore, 2004; Fischbach and Walsh, 2009).
In an attempt to guide research and development toward
the most critical pathogens, the World Health Organization
(WHO) recently published their ‘global priority list,’ containing
12 bacterial pathogens that raise particular concern (WHO,
2017). Among these are the so-called ESKAPE pathogens,
Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, P. aeruginosa, and
Enterobacter spp., which efficiently evade antibiotic treatment
and represent new paradigms in pathogenesis, transmission,
and resistance (Rice, 2008). Together, this select group of
bacteria is responsible for most of the hospital-acquired
infections and, despite increasing research efforts, therapeutic
options remain scarce (Bassetti et al., 2013; Pendleton et al.,
2013). Greatly contributing to the difficult treatment of
these bacterial infections is the presence of non-growing
persister cells. These phenotypic variants show a reduced
metabolic activity, are able to withstand intensive antibiotic
treatment, and when antibiotic pressure drops, are capable
of restoring the bacterial population, causing recurrence of
infection (Fauvart et al., 2011; Van den Bergh et al., 2017).
Persistence is widely acknowledged as a major culprit of
treatment failure in chronic and biofilm infections and recent
research has identified the persister fraction as a possible
reservoir for the development of resistance (Lewis, 2007;
Cohen et al., 2013). Effective elimination of persister cells
could significantly improve patient outcomes, but their small
numbers and the apparent redundancy in persister mechanisms
greatly hampers the development of targeted anti-persister
therapies.
We recently reported the identification of a novel anti-
persister molecule capable of directly killing persister cells
of P. aeruginosa (Liebens et al., 2017). SPI009 was identified
in a screening of 23,909 small molecules for compounds
that decrease the persister fraction of P. aeruginosa in
combination with the conventional antibiotic ofloxacin.
In the present study, we explore the activity of SPI009
in several additional pathogens and demonstrate broad
spectrum activity and the ability to sensitize resistant strains.
Furthermore, SPI009 was shown to retain activity in different
biofilm models and is capable of significantly improving
antibiotic efficacy both in in vitro and in vivo infection
models. Overall, these results further increase the clinical
potential of SPI009 and offer compelling perspectives for
the use of SPI009 as an adjuvant in effective antimicrobial
therapies.
MATERIALS AND METHODS
Bacterial Strains, Human Cell Lines,
C. elegans, and Culture Conditions
Bacterial strains used in this study are listed in Table 1. All
strains were cultured in 1:20 diluted Trypticase Soy Broth (1/20
TSB) at 37◦C shaking at 200 rpm. For solid medium, TSB
was supplemented with 1.5% agar. Human THP-1 cell lines
were cultivated in RPMI-1640 medium containing 10% fetal
calf serum at 37◦C with 5% CO2. The C. elegans AU37 strain
[glp-4(bn2); sek-1(km4)] was obtained from the Caenorhabditis
Genetics Center (CGC) and maintained according to standards
(Stiernagle, 2006). The following antibacterials were used:
ofloxacin, ciprofloxacin, rifampicin, polymyxin B, vancomycin
(Sigma–Aldrich), and 1-[(2,4-dichlorophenethyl)amino]-
3-phenoxypropan-2-ol (SPI009; CD3) with concentrations
indicated throughout the text.
Antibacterial Assays
Antibacterial assays were performed on different clinically
relevant pathogens as previously described (Liebens et al.,
2017). Briefly, stationary phase cultures were treated for 5 h
with 17 or 34 µg/mL of SPI009 alone or in combination
with an appropriate antibiotic to assess anti-bacterial and anti-
persister effects, respectively. To evaluate activity against resistant
strains, stationary phase cultures were treated for 5 h with 1x,
4x, and 8x MIC concentrations of the respective antibiotic;
17 or 34 µg/mL SPI009 or the combination of both. After
treatment, cells were washed and viability was assessed via
plating.
Quantification of Biofilm Formation and
Eradication after Treatment with SPI009
Overnight cultures of P. aeruginosa PA14 WT or S. aureus ATCC
33591 were diluted 1:100 in 1/20 TSB medium supplemented
with 2% DMSO (carrier control) or increasing concentrations
of SPI009 (4.25–68 µg/mL). Biofilms were grown for 24 h at
37◦C on the bottom of a polystyrene 96-well plate, non-shaking.
Medium and free-living cells were removed and the biofilms
were washed, scraped off and passed five times through a syringe
(0.5 mm × 1.6 mm) to disrupt any cell clumps and obtain single
cells (Hermans et al., 2011). Appropriate dilutions made in 1x
PBS were plated on solid TSB agar plates to assess biofilm growth
under different conditions.
To explore the biofilm eradicating effects of SPI009, overnight
cultures of P. aeruginosa PA14 WT or S. aureus ATCC 33591
were diluted 1:100 in 1/20 TSB medium and incubated for 24 h
at 37◦C (non-shaking). Mature biofilms were treated for 5 h
with 2% DMSO and increasing concentrations of SPI009 (8.5–
136 µg/mL) at 37◦C, non-shaking, after which the remaining
biofilms were processed as described above.
Chronic Wound Model
A three-dimensional wound biofilm model was used, as
previously described (Townsend et al., 2016). P. aeruginosa
coated cellulose matrices, obtained after 2 h of adhesion (1× 106
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TABLE 1 | Strains used in this study.
Strain Description Source or reference
P. aeruginosa PA14 Wild type; UBCPP-PA14 Pierre Cornelis; Lee et al., 2006
P. aeruginosa PAO1 Wild type Dieter Haas (ETH)
P. aeruginosa PA62 Broncho-pulmonary clinical isolate OFXR, CIPR, GENR, AMKR, ATMR, TICR,
PIPR, TZPR, CAZR, FEPR
Françoise van Bambeke (UCL)
P. aeruginosa 9BR Clinical isolate, PBMR, MEMR, CIPR, and FEPR, CAZR, or TZPR Bob Hancock; Boyle et al., 2012
E. aerogenes ATCC 13048 (KCTC 2190) Shin et al., 2012
S. aureus Rosenbach 1844 Wild type, methicillin resistant, ATCC 33591 BCCM/LGM bacterial collection; Conlon et al., 2013
K. pneumoniae ATCC 13883 Arivett et al., 2015
A. baumannii RUH134 Jean-Paul Pirnay; Merabishvili et al., 2014
E. faecium LMG 8148 Descheemaeker et al., 1997
B. cenocepacia K56-2 LMG 18863 Van Acker et al., 2013
E. coli BW25113 F−, 1(araD-araB)567, 1lacZ4787(::rrnB-3), λ−, rph-1, 1(rhaD-rhaB)568,
hsdR514
Baba et al., 2006
Resistance profiles determined according to EUCAST MIC breakpoints (European Committee on Antimicrobial Susceptibility Testing, 2017). OFX, ofloxacin; CIP,
ciprofloxacin; GEN, gentamicin; AMK, amikacin; ATM, aztreonam; TIC, ticarcillin; PIP, piperacillin; TZP, piperacillin-tazobactam; CAZ, ceftazidime; FEP, cefepime; PBM,
polymyxin B; MEM, meropenem.
cells/mL), were placed onto the hydrogels after which 3D biofilm
development was allowed for 24 h at 37◦C. Mature biofilms
were treated for 24 h with DMSO (1%), 10 µg/mL ofloxacin, 34
and 69 µg/mL of SPI009 or the combination of ofloxacin and
SPI009. Any non-adherent cells were removed by rinsing after
which biomass was removed by sonication at 35 kHz for 10 min
and DNA was extracted. Samples were prepared as previously
described and viability-based qPCR using P. aeruginosa
specific primers F- GGGCGAAGAAGGAAATGGTC and
R- CAGGTGGCGTAGGTGGAGAA was used to determine live
and total fractions of biofilm cells under different treatment
conditions (Smith et al., 2016). Standard curves were used to
convert the obtained qPCR values to colony forming estimates
(CFEs), after which log10-transformed values were used for
statistical analysis, as described below. All experiments were
carried out in triplicate, each containing three technical
repeats.
Intracellular Infection Model
Infection of human THP-1 cells was performed as described
previously, with minor modifications (Buyck et al., 2013).
Since a newly synthesized batch of SPI009 was used for this
experiment, cytotoxicity assessment via an LDH enzyme
assay was repeated for the THP-1 cell line, as previously
described (Liebens et al., 2017). After THP-1 infection with
P. aeruginosa PAO1 and subsequent removal of any non-
phagocytozed or adherent bacteria, ciprofloxacin and SPI009
were added in final concentrations of, respectively, 0–20 µg/mL
and 6.8 or 10.2 µg/mL. After 5 h of treatment, eukaryotic
cells were collected in three consecutive centrifugation
steps and complete cell lysis was obtained by sonication
(10 s). Lysates were used for bacterial CFU counting and
determination of protein content by Lowry’s assay (Bio-Rad
DC protein assay kit; Bio-Rad laboratories, Hercules, CA,
United States). For analysis of surviving bacterial cells, CFU
data were divided by corresponding protein content for
normalization.
C. elegans Toxicity Testing and Survival
Assay
AU37 nematodes were synchronized as previously described
(Porta-de-la-Riva et al., 2012) to obtain L4 worms suitable for
toxicity and infection assays (Briers et al., 2014). Larvae obtained
after bleaching were plated onto solid NGM-OP50 agar plates
and incubated at 25◦C during 2 days to allow development of the
worms to the L4 stage. Worms were transferred to fresh NGM
agar plates containing OP50 (toxicity testing and uninfected
control) or PA14 (infection) for an additional 24 h at 25◦C.
To evaluate toxicity of SPI009 L4 nematodes grown on OP50
were transferred to 12-well plates (20–30 worms/well) containing
different concentrations of SPI009 (8.5–136 µg/mL) in 1.5 mL
NGM:M9 (1:4). Controls consisted of untreated worms and
DMSO (2% and 20%). For the infection assay, adult worms
were allowed to feed on NGM-PA14 plates for 24 h, after which
residual bacteria were removed and nematodes were divided over
a 12-well plate (20–30 worms/well). Different treatments were
prepared in 1.5 mL NGM:M9 (1:4) and consisted of an untreated
control, 1.56 µg/mL ciprofloxacin (5x MIC), 8.5 µg/mL of
SPI009 and the combination of ciprofloxacin and SPI009. As an
additional control, uninfected worms were included. For both
assays, worms were incubated at 25◦C and survival was scored
visually for 6 days.
Statistical Analysis
Unless mentioned otherwise, all statistical analyses were
performed on log10-transformed data using GraphPad Prism
software (version 6.01). Bacterial survival after different
treatments was compared to the untreated or antibiotic control
using a one-way ANOVA (α = 0.05), with Dunnett’s correction
for multiple comparisons. Statistical comparison of mono-
and combination treatment in resistant strains was done using
a two-way ANOVA (α = 0.05) with Tukey correction for
multiple comparisons. Statistical analysis of the in vivo C. elegans
data was done by means of a log-rank test using GraphPad
Prism.
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RESULTS
SPI009 Shows Broad-Spectrum Activity
against Different Clinically Relevant
Bacterial Species
The activity of SPI009 was previously assessed in P. aeruginosa
PA14 and several clinical isolates where combination with
ofloxacin significantly decreased the persister fraction in all
strains tested (Liebens et al., 2017). In the present study, we
challenged a panel of clinically relevant species, including the
ESKAPE pathogens (Figure 1A), B. cenocepacia and E. coli
(Figure 1B). For each species appropriate concentrations
of a conventional antibiotic used in the clinic were selected
to allow only persister cells to survive (Supplementary
Figure S1). Combination of the antibiotic with 17 µg/mL
SPI009 significantly decreased the number of surviving bacteria
for five of the eight species with reductions in CFU ranging
between 1.5 ± 0.1 and 6.0 ± 0.2 log units and complete
eradication of K. pneumoniae. Addition of 34 µg/mL completely
eradicated the bacterial cultures of five of the eight species
tested and resulted in significant 6.6 ± 0.5 log, 6.2 ± 1.3 log,
and 5.4 ± 0.5 log reductions in bacterial survival for S. aureus,
E. faecium, and B. cenocepacia, respectively. No reduction in
survival is observed after treatment with 17 µg/mL for either
of the Gram-positive species, E. faecium and S. aureus. These
results suggest that the latter two species, and the Gram-negative
B. cenocepacia, are slightly less sensitive toward the combination
therapy. K. pneumoniae proved the most susceptible species
toward SPI009. Overall, the obtained results further support
the antibacterial effect of SPI009 and reveal a broad-spectrum
activity.
SPI009 Sensitizes Antibiotic-Resistant
Strains
To investigate the possible use of SPI009 as an adjuvant
in antibacterial combination therapies, several (multi)drug-
resistant strains were treated with 1x, 4x, and 8x MIC
concentrations of the antibiotic, alone and in combination with
SPI009. While SPI009 alone did not cause a significant decrease
in survival of the ofloxacin resistant P. aeruginosa PA62, addition
of 17 or 34 µg/mL of SPI009 significantly reduced the number of
surviving cells by 5.3 ± 0.9 and 7.8 ± 0.9 log units at 4x MIC of
ofloxacin while combination with 8x MIC completely eradicated
the bacterial culture (Figure 2A). In comparison, treatment with
ofloxacin alone caused 0.8 ± 0.9 log and 2.8 ± 0.9 log decreases
in surviving cells at concentrations of 4x MIC and 8x MIC,
respectively.
A similar trend was observed in the polymyxin B resistant
P. aeruginosa 9BR (Figure 2B). Here, addition of the antibiotic
alone had a slightly greater effect but combination with SPI009
still significantly improved the treatment and 17µg/mL of SPI009
successfully eradicated the entire bacterial culture in combination
with 4x MIC of polymyxin B. A somewhat smaller effect was
observed in the polymyxin B resistant B. cenocepacia strain
K56-2, for which addition of 17 µg/mL and 34 µg/mL SPI009
to 4x MIC polymyxin B resulted in significant 4.9 ± 0.5 and
FIGURE 1 | SPI009 possesses broad-spectrum activity against different
clinically important pathogens. 200 µL volumes of stationary phase cultures of
(A) ESKAPE pathogens E. aerogenes, S. aureus, K. pneumoniae, A.
baumannii, P. aeruginosa, and E. faecium and (B) B. cenocepacia and E. coli
were treated for 5 h with the combination of a conventional antibiotic;
ofloxacin (OFX), ciprofloxacin (CIP), or rifampicin (RIF) and 17 or 34 µg/mL
SPI009. Black bars represent the antibiotic and white bars the combination of
antibiotic with SPI009. Results are the mean of at least three independent
experiments with error bars depicting SEM values. One-way ANOVA with
Dunnett’s correction for multiple comparisons was used to detect significant
differences to the antibiotic control with ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001,
∗∗∗∗P ≤ 0.0001. ND, not detected.
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FIGURE 2 | SPI009 re-enables the treatment of (multi)drug-resistant strains. Stationary phase cultures of (A) P. aeruginosa PA62 (OFXR), (B) P. aeruginosa 9BR
(PMBR) and (C) B. cenocepacia K56-2 (PMBR) were treated for 5 h with 1x MIC, 4x MIC, and 8x MIC concentrations of the respective antibiotic alone and in
combination with 17 or 34 µg/mL of SPI009. Data points represent the average of at least three biological repeats. SEM values are shown as error bars. Statistical
analysis was done by means of two-way ANOVA (α = 0.05) with Tukey correction for multiple comparisons and ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001,
∗∗∗∗P ≤ 0.0001; ND, not detected.
FIGURE 3 | Anti-biofilm effects of SPI009 in P. aeruginosa and S. aureus. Increasing concentrations of SPI009 (4.25–136 µg/mL) and a DMSO control were added
for (A) 24 h to 1:100 diluted cultures or (B) 5 h to 24-h-old biofilms in 96-well microtiter plates to assess biofilm inhibition and eradication, respectively. After
treatment, biofilms were washed, disturbed and plated out to calculate the number of surviving cells. Data points represent the percentage of surviving cells relative
to the untreated control as an average of at least three biological repeats, each containing three technical repeats. Error bars depict SEM values. Statistical
significance was calculated on log10 transformed CFU counts using a one-way ANOVA with Dunnett’s correction for multiple comparisons. ∗P ≤ 0.05, ∗∗P ≤ 0.01,
∗∗∗P ≤ 0.001, ∗∗∗∗P ≤ 0.0001. ND, not detectable.
5.2 ± 0.5 log decreases in survival. Combinations with higher
concentrations of polymyxin B (8x MIC) did not further decrease
the number of surviving cells (Figure 2C). The obtained results
clearly demonstrate the effective use of SPI009 as an adjuvant
for antibacterial therapy thereby facilitating the treatment of
different antibiotic-resistant strains. Furthermore, SPI009 retains
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activity in multidrug-resistant strains, revealing the lack of cross-
resistance. Importantly, resensitization of resistant strains could
restore the effectiveness of established antibiotics.
Biofilm Inhibition and Eradication Effects
of SPI009
To assess biofilm inhibiting properties of SPI009 in P. aeruginosa
and S. aureus, biofilm growth was allowed in the presence
of increasing concentrations of SPI009 (Figure 3A). Analysis
of the obtained results clearly show an effective inhibition
of biofilm growth in both P. aeruginosa and S. aureus. For
P. aeruginosa, a steep increase in inhibitory activity was observed
at concentrations above 8.5 µg/mL, resulting in 1.8± 0.5 log and
2.4 ± 0.4 log decreases at 17 or 34 µg/mL SPI009, respectively,
and complete inhibition of biofilm growth at 68 µg/mL. S. aureus
showed a more gradual decrease in biofilm formation with
34 µg/mL and 68 µg/mL resulting in significant 6.2 ± 0.6 log
and 6.4 ± 0.6 log decreases in biofilm formation, respectively.
These results clearly demonstrate the potent biofilm inhibiting
activity of SPI009 for both Gram-negative and Gram-positive
model pathogens.
To explore biofilm eradication, SPI009 was added to mature
biofilms and survival was assessed after 5 h of treatment. For
P. aeruginosa the lower concentrations (8.5 and 17 µg/mL)
caused a decrease in biofilm survival of about 0.8 log units
(Figure 3B). Doses of 34 µg/mL or higher significantly decreased
the number of surviving biofilms cells, resulting in 4.2 ± 0.6;
6.2± 0.6; and 6.6± 0.6 log reductions. In comparison, 10 µg/mL
of the conventional antibiotic ofloxacin caused a significant
4.5 ± 1 log decrease in the number of surviving biofilm cells
(Supplementary Figure S2A). For S. aureus, the treatment of
mature biofilms with lower concentrations of SPI009 proved
slightly less effective than for P. aeruginosa. Treatment with
higher concentrations did cause extensive damage, resulting
in significant decreases in biofilm survival ranging between
2.5 ± 0.7 and 5.4 ± 0.6 log. For the 96-well biofilm models used
in this study, the combination of SPI009 with a conventional
antibiotic did not further decrease the number of surviving cells
as compared to mono-treatment with SPI009 (Supplementary
Figure S2). Overall, SPI009 shows potent activity in biofilms of
both Gram-negative and Gram-positive species and is capable of
significantly inhibiting biofilm formation and decreasing survival
of mature biofilms.
SPI009 Reduces Bacterial Load in a
Chronic Wound Model
After confirming the biofilm eradication capacity of SPI009
in a standard biofilm set-up, a more clinically relevant model
was used to assess the clinical potential of SPI009 as a topical
antibacterial treatment. Using a porous cellulose matrix placed
upon a moist hydrogel allowed the growth of a complex, three-
dimensional hydrated structure, effectively mimicking biofilms
in a chronic wound environment (Townsend et al., 2016;
Kean et al., 2017). Assessment of viability was performed
by means of live/dead quantitative PCR (Figure 4). For the
viable cells, treatment with increasing concentrations of SPI009
FIGURE 4 | Effect of SPI009 in a chronic wound model. Mature biofilms,
grown on hydrogels supporting a cellulose matrix, were treated for 24 h with
10 µg/mL ofloxacin, 34 or 68 µg/mL of SPI009 alone or in combination with
ofloxacin. Washed biofilms were removed by sonication and viability was
assessed by means of Live/Dead PCR. Values are shown as the log10
transformation of colony forming estimates (CFEs), as determined for three
biological repeats each containing three technical repeats. Error bars
represent SEM values. Significant differences relative to untreated control are
depicted by ∗, # represent significant differences relative to ofloxacin treatment
with ∗/# P ≤ 0.05, ∗∗/## P ≤ 0.01, as determined by means of one-way
ANOVA with Dunnett’s correction.
alone resulted in significant 1.6 ± 0.5 log (34 µg/mL) and
2.0 ± 0.5 log (68 µg/mL) decreases in the number of surviving
cells. The obtained results confirm the biofilm eradication
capacity of SPI009, both as an antimicrobial and as part of
a combination therapy, and this in a more complex, realistic
biofilm environment.
SPI009 Potentiates Antibiotic Activity in
an Intracellular Infection Model
Next, the anti-persister and antibacterial activities of SPI009
were verified in a recently developed P. aeruginosa intracellular
infection model (Buyck et al., 2013). Human THP-1 cells
were infected with PAO1 cells (MOI 10) and treated for
5 h with different concentrations of ciprofloxacin, alone or in
combination with 6.8 or 10.2 µg/mL of SPI009. Concentrations
of SPI009 were chosen to be well below the determined
IC50 value of 24.5 ± 1.36 µg/mL. After treatment, both
the number of surviving PAO1 cells and the amount of
eukaryotic proteins present was assessed, as this can provide
information about the possible toxic effect of the different
treatments and the infecting bacteria. While treatment with
SPI009 alone caused non-significant decreases of 0.78 ± 0.7
and 0.89 ± 0.7 log units in surviving bacteria, addition of
SPI009 to ciprofloxacin greatly improved the antibacterial effect
for all concentrations tested and this in a dose-dependent
manner (Figure 5). Maximal antibacterial activity for the
combination therapy with 10.2 µg/mL of SPI009 occurs at
ciprofloxacin concentrations of 10 µg/mL, resulting in complete
eradication of the bacterial culture. Moreover, all combinations
tested significantly reduced the bacterial load as compared to
ciprofloxacin alone. Combination treatment with 6.8 µg/mL
SPI009 showed a maximal 0.78 ± 0.6 log decrease as compared
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FIGURE 5 | Addition of SPI009 enhances antibiotic treatment of intracellular
infections. Human THP-1 cells were infected for 5 h with P. aeruginosa PAO1
(MOI 1:10) after which extracellular bacteria were removed and cells were
treated with increasing concentrations of ciprofloxacin, alone or in
combination with 6.8 µg/mL or 10 µg/mL of SPI009. Data points represent
the average of at least two biological repeats, each containing three technical
repeats. Error bars depict SEM values. Statistical comparison between
ciprofloxacin treatment and the different combination treatments was done by
means of one-way ANOVA testing with correction for multiple comparisons
(Dunnett) (α = 0.05).
to antibiotic alone at a ciprofloxacin concentration of 20 µg/mL.
These results clearly show that SPI009 can effectively penetrate
the eukaryotic cell membrane, without causing extensive damage,
to eradicate the intracellular P. aeruginosa infection.
SPI009 Combination Therapy
Significantly Improves in Vivo Survival
Since the antibacterial effect of SPI009 was demonstrated
extensively in vitro, a next step was to assess the effect of
this new compound in an in vivo C. elegans gut infection
model. Toxicity testing of SPI009 in C. elegans revealed minor
levels of toxicity at 68 µg/mL and >80% killing at 136 µg/mL
(Supplementary Figure S3), excluding these concentrations
from further experiments. Analysis of the different DMSO
concentrations suggests that the observed toxicity is mainly
caused by increasing concentrations of the solvent.
Infection of nematodes with PA14 resulted in 91.5% killing
within 6 days after the start of infection, confirming the highly
virulent nature of the PA14 strain in this model (Figure 6).
Addition of 8.5 µg/mL of SPI009 alone slightly improved survival
but not as good as 5x MIC of ciprofloxacin, resulting in survival
rates of 19.0% (P = 0.045) and 46.6% (P < 0.0001), respectively.
However, addition of 8.5 µg/mL of SPI009 to ciprofloxacin
greatly increased survival, resulting in 73.8% nematode survival
after 6 days. These results show a significant improvement in
antibacterial effect of the combination therapy compared to the
untreated (P < 0.0001) and ciprofloxacin-treated (P = 0.0001)
controls (Supplementary Table S1). Since low doses of SPI009 can
greatly enhance the effect of conventional antibiotic treatment,
resulting in more than 73% survival, these results indicate the
highly efficient antibacterial and potentiating effect of SPI009 as
part of a combination therapy.
FIGURE 6 | SPI009 combination therapy enhances C. elegans survival in a
PA14 WT infection assay. 1glp-4(bn2)/1sek-1(km4) C. elegans worms were
infected with P. aeruginosa by feeding them on NGM-PA14 WT plates for 24 h.
Worms were treated with 8.5 µg/mL SPI009 (open diamonds), 1.56 µg/mL
ciprofloxacin (5x MIC; open triangles) or the combination of SPI009 with
ciprofloxacin (filled circles). Untreated worms (open squares) and uninfected
worms (solid line) served as controls. Worms were counted daily for 6 days
with nematode survival expressed as a percentage relative to the viability on
day 1. Data points represent the mean of at least three independent
repeats ± SEM. Statistical analysis was performed on Kaplan–Meier plots by
means of the log-rank test (α = 0.05). Significant differences to the untreated
control are represented by ∗, # represent significant differences to the
ciprfloxacin control. ∗P ≤ 0.05, ###P ≤ 0.001 and ∗∗∗∗ P ≤ 0.0001.
DISCUSSION
Decades of excessive drug prescription, misuse of antimicrobials
and extensive agricultural applications have caused a massive
increase in drug resistance. Conventional antibiotic therapies
are losing the battle against emerging extensively drug-resistant
strains, resulting in 25,000 annual deaths in the European
Union (European Centre for Disease Prevention and Control,
2009). A group of pathogens raising particular concern are
the so-called ESKAPE pathogens, E. faecium, S. aureus, K.
pneumoniae, A. baumannii, P. aeruginosa, and Enterobacter
spp. Responsible for the majority of nosocomial infections,
these pathogens show significant rises in resistance rates and
are becoming increasingly difficult to treat with currently
available antibiotics (Boucher et al., 2009; Pendleton et al.,
2013). Since it is becoming alarmingly difficult to identify
novel antibiotic targets, combination therapies could provide
an alternative strategy for the effective treatment of bacterial
infections. When different mode of actions are combined, they
can lower the risk of resistance development and extend the
life span of currently available antibiotics (Tamma et al., 2012;
Gill et al., 2015). However, additional research is needed to
assess possible negative effects associated with combination
therapies and to determine an optimal combination in vivo
(Tamma et al., 2012; Pena-Miller et al., 2013). An additional
advantage of combination therapies is their potential use in
the treatment of persister cells (Cui et al., 2016; Feng et al.,
2016; Yang et al., 2016; Gallo et al., 2017; Koeva et al., 2017), a
small reservoir of phenotypical variants that tolerate antibiotic
treatment and reinitiate bacterial infection when the antibiotic
pressure drops. The antibiotic-tolerant phenotype of persister
cells contributes to the recalcitrant nature of chronic infections,
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greatly complicates treatment and increases the chances of
resistance development (Lewis, 2007; Fauvart et al., 2011;
Michiels et al., 2016).
We recently described the discovery of the propanol-amine
derivative SPI009, a novel anti-persister molecule capable of
directly killing persister cells of P. aeruginosa (Liebens et al.,
2017). Most anti-persister molecules described in literature
are only active against one or a very limited number of
bacterial species, which can be explained by a very specific
mode of action or the sensitizing of persister cells to a
specific class of antibiotics (Wood, 2015; Van den Bergh et al.,
2017). Other examples of small organic compounds capable
of directly killing persister cells include the recently described
α-bromocinnamaldehyde (Shen et al., 2017), 5-iodoindole (Lee
et al., 2016), halogenated phenazines (Garrison et al., 2015) and
the nitroimidazole prodrug PA-284 (Singh et al., 2008). In this
study, we showed that SPI009 possesses broad-spectrum activity
and is capable of significantly decreasing or even eradicating
the bacterial culture for all pathogens tested, including the
notorious ESKAPE pathogens. In addition, combination therapy
of conventional antibiotics with SPI009 allowed the efficient
treatment of polymyxin B and ofloxacin resistant strains and
could lower the required concentration of antibiotics, thereby
enabling their use in resistant strains.
The close relationship between persisters and chronic
infections (LaFleur et al., 2006; Mulcahy et al., 2010) is partly
caused by their presence in biofilms. The presence of the biofilm
matrix is capable of physically protecting the persister cells
against the human immune system, thereby enabling the persister
cells to resume growth when antibiotic pressure drops and cause
recurrence of infection. When compared to other anti-biofilm
compounds or conventional antibiotics, SPI009 monotherapy
shows a promising anti-biofilm effect, both decreasing biofilm
formation and causing a strong reduction in the number of
surviving biofilm cells, for both Gram-negative and Gram-
positive species. A more clinically relevant biofilm model was
obtained by P. aeruginosa growth on cellulose matrices and
hydrogels, providing a three-dimensional structure and moist
environment closely mimicking the environment of a chronically
infected wound. In this 3D model, clinical treatments have
been shown to have less impact on the viability of biofilms in
comparison to traditional 2D models, which are more susceptible
to eradication (Townsend et al., 2016; Kean et al., 2017).
Therefore this further supports the ability of SPI009 mono-
treatment to eradicate cells in a more complex biofilm model
and suggests the possible use of SPI009 in the topical treatment
of chronically infected wounds. For all biofilm experiments
executed, the addition of SPI009 to a conventional antibiotic
did not further decrease the biofilm population as compared
to SPI009 alone. In comparison to planktonic cultures, where
combination therapy with antibiotics strongly enhances the
antibacterial effect, the specific lay-out and environment of
the bacterial biofilm, including a possibly reduced penetration
of antibacterials, could impair the cooperation between both
antibacterials.
Besides the biofilm matrix, persister cells have also been shown
to use eukaryotic cells to shield themselves from the human
immune system. The presence of intracellular persister reservoirs
has been confirmed in vivo and can be associated with the
chronic nature of infections (Buyck et al., 2013; Helaine et al.,
2014). The ability of SPI009 to effectively reduce the intracellular
bacteria further confirms the potential of SPI009 as an adjuvant in
combination therapies. Capable of increasing nematode survival
to more than 70% when combined with ciprofloxacin, the in vivo
C. elegans model further contributes to the clinical potential
of SPI009. The C. elegans model has been extensively used in
the identification and clinical assessment of novel antibacterials
and antifungals with ample studies confirming the consistent
correlation between toxic effects in C. elegans and mammalian
models (Hunt, 2017).
CONCLUSION
We demonstrated that the anti-persister molecule SPI009
possesses a broad-spectrum antibacterial activity and, taken
into account that it can be combined with different classes
of antibiotics, shows great potential for the development of
case-specific antibacterial combination therapies. The clinical
potential of SPI009 was further confirmed by the observation
of an excellent anti-biofilm activity, successful eradication
of an intracellular infection in human eukaryotes and the
significant increase in C. elegans survival after treatment with
the combination of SPI009 and ciprofloxacin. Additional in vivo
experiments will be required to assess the future applicability
of SPI009 but its excellent activity in antibacterial combination
therapies holds great promise.
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